# Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

> **NCT03965871** · PHASE2 · COMPLETED · sponsor: **Celon Pharma SA** · enrollment: 88 (actual)

## Conditions studied

- Bipolar Depression

## Interventions

- **DRUG:** Esketamine DPI - low dose
- **DRUG:** Esketamine DPI - medium dose
- **DRUG:** Esketamine DPI - high dose
- **DRUG:** Placebo DPI

## Key facts

- **NCT ID:** NCT03965871
- **Lead sponsor:** Celon Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2021-01-03
- **Final completion:** 2021-02-19
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2021-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965871, "Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03965871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*